Claus Bo Svendsen MD PhD MBA

Copenhagen Nanosystems (cphnano.com) is a Danish Labtech company that develops solutions for particle size analysis and UV-Vis spectroscopy. We work with upgrading UV-Vis spectrophotometry across all brands to be at the forefront at the technology development. We expand the functionality of existing spectrophotometers by developing plastic labware with nanotechnology and analyzing data in the cloud - leading to faster and more accurate results in the laboratory while lowering upfront investments. The NanoCuvettes™ unlocks the full potential of the spectrophotometer and SpectroWorks™ optimizes and automizes your UV-Vis instrument workflow.

Alpine-bio is a data driven life science niche company with focus on indication discovery within selected therapeutic areas, technology and foodtech. We utilise technology such as Generative AI in our work, which creates an innovative approach to determining fulfilment of unmet medical needs in order to serve patients and caregivers with the best possible solutions, and in the fastest possible way. We utilise data to analyse new projects and opportunities, so we can say yes and no based on factual information. We focus our growth and development through selected M&A transactions, partnerships and licensing. We work with an array of companies and partner within all aspects of the pharmaceutical value chain being from contract manufacturing, regulatory, compliance, warehousing, distribution, local marketing and sales, and pharmacovigilance. We are a core set of founders, but an extended team of currently some 60-70 people that we can activate depending on the project and area. Alpine-Bio is first mover in using Generative AI, combining the deep knowledge and experience within the leadership for AI, technology and pharmaceutical development and commercialization.

The Mission Fund invests in pre-proof-of-concept therapeutic companies with potentially curative therapies that require a killer experiment to validate the science behind their therapy being potentially curative. We focus on cancer, mental health and age related degeneration.

The Innovation Fund Denmark invests in the development and marketing of knowledge, new technologies and products with the purpose of finding solutions to societal challenges, support business opportunities and strengthen growth, employment and welfare. With the establishment of the Innovation Fund April 1 2014 the Danish research and innovation system was significantly simplified. The Foundation will be offering grants for activities within strategic research, technology and innovation. The budget of the Foundation is close to DKK 1.6 billion in 2014. The Innovation Fund Denmark will contribute to stronger coherency across research, technological development and innovation, including community partnerships focused on product development and innovation.

S21 Advisory offers consulting services to life science companies and investors with focus on clinical development & regulatory strategy, due diligence, investment analysis and business development. Examples: *Strategic Development Regulatory and Clinical Development Strategy New indication or product planning Business case development and challenge * Due diligence Investment decisions, valuation Turnaround strategies * Capital Markets Strategy Investor Relations Pitch deck development Experience with Series A-B, IPO Management, compliance and delisting of a U.S. public company * Interim or project management Executive Level / Managing Director R&D organization * Non-executive board director or board advisor Currently working in: amyotrophic lateral sclerosis, major depressive disorder. Previous experience in: multiple sclerosis, Friedreichs Ataxia, psoriasis, major depressive disorder, bipolar disorder, diabetes mellitus and obesity. Feel free to reach out for a discussion on how I can help you at claus@s21advisory.com / +45 81771250.

Forward Pharma A/S was a Danish biopharmaceutical company that from 2005 to 2017 developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The company completed a voluntary solvent liquidation in 2025.